Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Acrux Says Europe Marketing Authorization for Recuvyra Granted

Oct. 13 (Bloomberg) -- Acrux Ltd. said the European Medicines Agency has granted the marketing authorization for commercial use of Recuvyra 50 mg/mL transdermal solution for dogs, according to a regulatory filing.

Link to Statement:{NSN LSZ7B53PR6RL <GO>}

Link to Company News:{ACR AU <Equity> CN <GO>} Link to Company News:{LLY US <Equity> CN <GO>}

To contact the editor responsible for this story: Victoria Batchelor at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.